BioNTech SE — 2021 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone Q4 filing; the supplied filing does not provide a clear set of Q4-only financial results. Financial statements are prepared under IFRS as issued by the IASB and reported in euros.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Total revenue | €18,976.7 million | €482.3 million |
| Commercial revenue | €18,874.0 million | €303.5 million |
| Operating income/(loss) | €15,283.8 million | (€82.4 million) |
| Profit/(loss) before tax | €15,046.4 million | (€145.8 million) |
| Net profit/(loss) | €10,292.5 million | €15.2 million |
| Basic / diluted EPS | €42.18 / €39.63 | €0.06 / €0.06 |
| Net cash from/(used in) operating activities | €889.7 million | (€13.5 million) |
| Cash and cash equivalents at year-end | €1,692.7 million | €1,210.2 million |
Calculated from reported figures, gross profit was approximately €16,065.2 million, or 84.7% of revenue; operating margin was approximately 80.5%, and net margin approximately 54.2%. These are derived measures, not separately presented filing metrics.
COMIRNATY revenue was €18,806.8 million. It included €14,828.7 million of recognized partner gross-profit share and sales milestones, €3,007.2 million of direct product sales, and €970.9 million of sales to collaboration partners. Research and development revenue was €102.7 million. Pfizer supplied preliminary sales and cost information used to estimate the profit share, particularly for non-U.S. territories.
Cash flow was affected by a €10,730.4 million net negative change in assets and liabilities, primarily from increased trade receivables. Year-end trade and other receivables were €12,381.7 million; BioNTech said €4,693.6 million had been collected by January 16, 2022. Separately, €375.2 million of six-month deposits classified as other financial assets at year-end returned to cash in January and February 2022.
Reported loans and borrowings were €301.5 million, including €181.6 million of lease liabilities and a €99.7 million convertible-note host liability. The embedded derivative associated with the note was separately reported as a €308.7 million liability. BioNTech announced it would redeem the note on March 1, 2022 through share issuance, with fractional shares and accrued interest paid in cash; it also agreed after year-end to repay two Deutsche Bank facilities totaling €19.5 million.
Material changes versus the prior comparable period
- Revenue rose sharply as BioNTech moved from a research-and-development revenue model to commercial vaccine sales. Commercial revenue increased from €303.5 million to €18,874.0 million.
- The company swung from €15.2 million net profit in 2020 to €10,292.5 million in 2021. Income taxes were €4,753.9 million, mainly reflecting taxable income in the German tax group.
- Research and development expense increased 47% to €949.2 million; sales and marketing expense rose to €50.4 million, and general and administrative expense to €285.8 million, reflecting program activity, hiring, commercialization and business expansion.
- Operating cash flow turned positive, but substantial receivables and the timing of partner settlements mean reported profit did not translate directly into year-end cash.
- Balance-sheet equity increased to €11,893.7 million from €1,371.8 million, largely reflecting 2021 earnings.
Outlook, commentary, risks and unusual items
- Management planned substantial investment in R&D, global development capabilities, manufacturing, infrastructure, acquisitions and broader therapeutic areas. No clear 2022 revenue or profit guidance is provided in the filing text.
- BioNTech and Pfizer reported 2021 deliveries of more than 2.6 billion vaccine doses and anticipated manufacturing capacity of up to four billion doses in 2022. As of mid-March 2022, they had signed 2022 orders for approximately 2.4 billion doses. These are forward-looking, post-year-end disclosures, not FY 2021 realized results.
- A proposed €2.00-per-share special dividend, approximately €486 million in aggregate, was subject to shareholder approval in June 2022. The filing also described a planned ADS repurchase authorization of up to $1.5 billion over two years.
- Key business risks include dependence on COVID-19 vaccine revenue, changing demand and competition, variants and duration of protection, pricing and reimbursement, manufacturing and cold-chain constraints, and reliance on preliminary Pfizer data. The company also faces clinical-development, regulatory, intellectual-property and product-safety risks.
- At year-end, BioNTech recorded a €177.9 million provision for pending or threatened claims, mainly involving alleged use of third-party intellectual property; management said settlement was not expected within 12 months. The outcome remains uncertain. Additional potential IP matters were not provisioned because recognition criteria were not met, and potential liability could not be estimated clearly.
- Other notable items included €194.6 million of vaccine inventory write-offs and reserves for quality specifications, regulatory requirements or shelf-life expiry; €58.5 million of provisions for customs and other international-trade obligations; and €35.4 million for inventor remuneration. The filing says some trade-related costs are subject to reimbursement under the Pfizer agreement.
- Internal reviews identified possible German wage-tax and social-security withholding and customs compliance issues. The company notified authorities; no administrative-offense or criminal proceedings had been opened as of the report date. It also reported that a material weakness identified in 2019 had been remediated, and management and the auditor concluded internal control over financial reporting was effective at December 31, 2021.
- The company reported a favorable audit opinion. The auditor identified revenue recognition for Pfizer’s vaccine sales as a critical audit matter because estimated partner sales and manufacturing and shipping costs may change when final data becomes available.
Most important facts for investors to verify
- Final Pfizer sales, cost and profit-share data, including any subsequent revenue or expense true-ups and collection of year-end receivables.
- 2022 vaccine orders, deliveries, production capacity and demand assumptions, including effects of variants, boosters, competition and pricing.
- Status and financial exposure of the €177.9 million IP provision, other potential patent claims and any related indemnification obligations.
- Resolution and potential cost of the tax-withholding and customs matters, including the recoverability of amounts from service providers or collaborators.
- Completion and terms of the convertible-note redemption and bank-loan repayments; approval and implementation of the proposed dividend and ADS repurchase program.
- Whether planned pipeline progress, manufacturing expansion and increased investment translate into durable revenue beyond COMIRNATY.